Advocacy & Policy Report

Accomplishments and Actions in 2021: Advocacy, Policy & 50-State Network

Steven Newmark, JD, MPA, Director of Policy
www.ghlf.org
TABLE OF CONTENTS

OUR FOCUS
Page 03

2022 SNAPSHOTS
Page 04

TEAM
Page 05

JANUARY
Page 08

FEBRUARY
Page 08

MARCH
Page 09

APRIL
Page 11

MAY
Page 14

JUNE
Page 16

JULY
Page 19

AUGUST
Page 21

SEPTEMBER
Page 22

OCTOBER
Page 23

NOVEMBER
Page 25

DECEMBER
Page 25

CONTACT US
Page 27
Advocacy, Policy & 50-State Network

In 2021 we continue to educate our patients about advocacy issues impacting their well-being as well as incorporate patients’ voices into our advocacy activities to ensure they are heard by key stakeholders across government and industry. Through outreach, education, and advocacy, we strive to create a world in which patients know that they are not alone and that their unique perspective is informing policymakers in the creation of health policy.
Federal comment and sign-on letters: 27

State comment letters: 12

Virtual meetings:
6 FEDERAL / 19 STATE

Special focus
MASSACHUSETTS AND PENNSYLVANIA

Individual legislator outreach
1,000+ CALLS AND EMAILS

Topics covered:
STEP THERAPY, COPAY ACCUMULATOR
ADJUSTORS, NON-MEDICAL SWITCHING

SUPPORTED 12 STATE BILLS THAT WERE
PASSED INTO LAW IN 2021
Steven serves as GHLF’s Policy Director, overseeing the entire policy and advocacy team. Steven’s vast experience in advocacy, and in particular vaccine-advocacy, has allowed GHLF to expand its reach. Steven’s background in organizing has helped expand the size of the 50-State Network, and his legal background enabled GHLF to join in multiple litigations to protect patient access. Steven is responsible for identifying relevant issue areas and working with the Advocacy Team to craft responses to help patients. He was most recently Special Counsel to the President of NYC Health + Hospitals in New York City. Before that he served as the Senior Health Policy Adviser to New York City Mayor Bill de Blasio. He also served as the Senior Health Policy Adviser to New York City Mayor Bill de Blasio’s Public Advocate office, and as a Health Sciences Litigation Associate at Orrick, Herrington & Sutcliffe, LLP in New York City where he was part of the team that successfully defended the Vaccine Act before the Supreme Court in Bruesewitz v. Wyeth. Additionally, he has taught Public Policy at Columbia University and is an Adjunct Professor in U.S. Health Policy at the City University of New York, Baruch College. He received his Juris Doctor from Fordham University School of Law and his Master of Public Policy and Administration, Advanced Policy and Management from Columbia University School of International and Public Affairs. He received his Bachelor of Arts, Philosophy, Politics and Law from the State University of New York at Binghamton.

Robert Popovian, PharmD, MS, Chief Science Policy Officer, is a healthcare/biopharmaceutical leader accomplished in pharmaceutical science, business and government, with a distinctive array of academic and practical experience across a wide range of healthcare and business management functions. Positioned at the intersection of economics, policy, and innovation which maximizes patient access, Dr. Popovian fosters an environment of performance, leadership, inclusiveness and innovation. In 2021, he joined GHLF after spending more than 20 years with Pfizer. His last position was as Vice President, U.S. Government Relations. A trained clinical pharmacist and a health economist and policy expert, he helps GHLF raise the voices of patients through his Patient-Focused Economic and Health Policy Research group.
Joseph Coe is the Director of Education and Digital Strategy. He has extensive knowledge and experience creating and sustaining grassroot and grasstop approaches to advocacy. He supports overall strategy and activation activities for our network. In addition, he oversees our migraine component of the 50-state network. When breaking advocacy challenges or opportunities occur he is first into action: getting information quickly into the hands of patients and allied stakeholders via social media.

Corey Greenblatt manages the 50-State Network state policy priorities and works with advocates across the country to show them how they can use their voice to advocate on behalf of patients. Corey organizes meetings with legislators and members of the 50-State Network and, along with Zoe Rothblatt, oversees the new CreakyKitchen cooking page. He earned a Master of Public Health at Columbia University’s Mailman School of Public Health, with a focus in Healthcare Policy Analysis. He received a Bachelor of Arts in International Studies and Public Health from the University of Miami. Corey has Type 1 diabetes, and prior to joining GHLF, he worked with the non-profit organization American Youth Understanding Diabetes Abroad (A.Y.U.D.A.) to provide outreach and education to children diagnosed with Type 1 Diabetes in Ecuador and the Dominican Republic.

Zoe Rothblatt engages in direct patient communications, legislative outreach and policy research. Zoe is responsible for understanding patient needs and creating patient-centered resources so patients can stay informed on their condition and care. Along with researching current policy initiatives, Zoe conducts direct communication with legislators to advocate on behalf of patients. She co-authored the widely cited report on step therapy which was peer-reviewed and published in *Health Economics Policy and Law*. She earned a Master of Public Health at Columbia University’s Mailman School of Public Health, with a focus on Health Policy and Management. She received a Bachelor of Arts in Health: Science, Society and Policy from Brandeis University. Prior to joining GHLF, Zoe worked at the Community Service Society of New York as a community health advocate providing direct service, advocacy, advice and referrals for patients needing assistance.
Conner Mertens works as a liaison between patient advocates and stakeholders. He helps ensure patients always have a voice wherever decisions are made regarding their care. He works directly with our 50-State Network members, empowering patients across the country to be their own best advocate. Since joining the GHLF team in 2019, he provides our community members with tools and training to effectively advocate for positive change. Conner interned for the Minority House Leader at the Oregon State Legislature, worked closely with legislators in Washington State passing mental health and suicide prevention laws, and was an intern at CNN New York, working in production and research for Anderson Cooper 360. In 2014, he was the first National Collegiate Athletic Association (NCAA) football player to come out publicly about his sexuality. He traveled the country speaking at high schools and universities, corporations, festivals and in state legislatures on topics such as anti-bullying, suicide-prevention, mental health, activism in sports and LGBTQ issues.

Angel Tapia is a bilingual patient advocate who supports, manages and grows our Hispanic community. Her native language Spanish survey and education projects reach people with high-credibility messages that are culturally tailored and geographically relevant. She is active on and manages relevant GHLF Spanish and English language social media and web platforms, including Instagram, Whatsapp and CreakyJoints.org.es. Angel received her BA from Golden Gate University and was a former Development Director for the Arthritis Foundation as well as an Education Director for Christus Health in Katy, Texas and the Ventura County Public Health Department, Ventura, California.

Sarah Shaw is a BIPOC Patient Advocate and Community Outreach Manager covering the chronic disease community, including neurology, autoimmune conditions, and oncology. As a migraine patient she also implements migraine patient activities and coalitions, as well as GHLF/CreakyJoints patient councils. She holds a B.A. in Journalism and Media and a minor in Labor Studies with a concentration in Diversity in the Workplace from Rutgers University. She is very involved in patient advocacy events and has been featured in various advocacy campaigns, including the Speak Your Migraine Campaign, WebMD’s “In Their Own Words: Moving Beyond Migraine” segment with Robin Roberts and an avid advocate at the lobbying event Headache on the Hill in Washington, D.C.
GHLF continues to submit letters to policymakers around the country to ensure patients who are their constituents have access to care without obstacles.

MONTH BY MONTH

JANUARY

Comment Letters:
1.7 – We joined a sign-on letter urging President Biden to rescind the human fetal tissue research restrictions and policy changes that the Department of Health and Human Services made in 2019.

Read the letter to President Biden about the significance of research using human fetal tissue.
Through outreach, education, and advocacy, we strive to create a world in which patients know that they are not alone and that their unique perspective is informing policymakers in the creation of health policy.

Congressional Briefing: Non-Opioid Pain Management for Chronically Ill Patients

On January 26th, we fostered an important discussion around pain management for those living with chronic conditions. Issue areas experts, including Congressman Brad Wenstrup (R-OH 2nd District), spoke about directly impacted patients and discussed how we can seek out innovative (non-opioid) solutions for pain management. Patient Advocate, Regina Greer-Smith, provided the patient perspective while GHLF Director of Policy, Steven Newmark, provided policy ideas on this subject.

Patient Advocacy:

Patient advocate JP Summers testified at a meeting of the Texas Drug Utilization Review Board (DURB) to fight for better migraine care.

Read More Here
FEBRUARY

Comment Letters:
2.5 – We joined a sign-on letter urging Congress to provide much needed funding to state and local public health departments to promote ACIP-recommended vaccinations and to combat vaccine hesitancy that lowers the immunization rate for both routine vaccines and COVID-19 vaccines.

Read the letter in support of Community Immunity During COVID-19 (H.R. 736/S. 167)

2.5 – We’ve been focused on stopping the continued growth of copay accumulator adjuster programs. We are concerned that the expansion of such programs will negatively impact patients’ ability to afford their medications.

Read the letter in support of New Mexico House Bill 129A which bans copay accumulator adjusters

Capturing more than 11 million impressions, the February #CreakyChats fostered an important conversation about health care topics to watch in 2021. These issues included non-medical switching, step therapy, biosimilars, health disparities, and telehealth. To help facilitate a rich discussion, Corey Greenblatt and Zoe Rothblatt, members of the GHLF 50-State Network team, cohosted the discussion.
**March**

**Comment Letters:**

3.2 – We joined a sign-on letter in support of a bill that takes important steps in setting the protections Rhode Island patients need to maintain access to copay assistance programs.

*Read the Letter in Support of Rhode Island House Bill 5438*

3.9 – We joined a sign-on letter in support of a bill that will protect patient access to copay assistance programs many Connecticut residents depend on to cover significant portions of prescription medicine copays.

*Read the Letter in Support of Connecticut Senate Bill 1003*

3.15 – We joined a sign-on letter in support of a bill that would establish a rare disease advisory council within the state and would help to give a voice to individuals living with a rare disease in South Carolina.

*Read the Letter in Support of South Carolina House Bill 3956*

3.25 – GHLF and our partner organization Lupus and Allied Diseases Association led a joint sign-on effort to bring together patient and provider groups in support of Senator Amy Klobuchar and her efforts to study the impact of rebate walls.

*Read the Letter in Support of Efforts to Examine Rebate Walls*
VIRTUAL ADVOCACY

We joined the Digestive Disease National Coalition’s 31st Annual Public Policy Forum to advocate for digestive disease research and improved patient care. In virtual meetings with Capitol Hill congressional offices, we shared our support for the Safe Step Act. We met with:

Senator Chuck Schumer  
Senator Kirsten Gillibrand

Congressman Sean Maloney  
Congressman Thomas Suozzi  
Congressman Paul Tonko  
Congresswoman Yvette Clarke

PATIENT ADVOCACY

Denise Marksberry testified at the Joint Arthritis Advisory Committee (AAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM) Meeting. “I am here today to put a face to the thousands of patients who will immediately benefit from a new treatment option” said patient advocate, Denise Marksberry, in her testimony for better osteoarthritis care.
APRIL

Comment Letters

4.16 – We joined a sign-on letter in support of a bill that established a Rare Disease Advisory Council in Florida, which would help give a voice to those living with rare disease.

Read the Letter in Support of Florida House Bill 1373

4.22 – We joined a sign-on letter urging CMS to reinstate the step therapy prohibition in Medicare Advantage plans for drugs.

Read the Letter to CMS About Step Therapy and Part B
VIRTUAL ADVOCACY

INSTAGRAM LIVE: HOW TO BECOME AN ADVOCATE FOR YOURSELF AND OTHERS

Patient advocates, Charis Hill, Roz Tolliver, and Zoe Rothblatt discussed what it’s like living with Spondyloarthritis. They shared their stories, how they got into advocacy and what awareness means to them.

Watch the Recording

Joseph Coe, MPA, Director of Education & Digital Strategy, spoke at Amgen’s 2021 Health Equity Summit in a session titled “Disrupt Health disparities Through Partnerships,” which was focused on the opportunities to create meaningful change.

OP-EDS

Elisa Comer, 50-State Network Patient Advocate, wrote an op-ed published in the Tennessean. Elisa shares her story in support of legislation that will protect Tennessee patients by ensuring they can use valuable patient assist programs.

Read the op-ed

Robert Popovian wrote an op-ed for Morning Consult about vaccine equity.

Read the op-ed

“"If this bill becomes law, patients just like me will not have to experience interruptions to their treatment, and compromises to their health could be prevented.” - Elisa Comer
Publication

Louis Tharp and Zoe Rothblatt were published in the peer-reviewed journal Health Economics, Policy and Law for a paper on step therapy entitled Do Patients Benefit from Laws Regulating Step Therapy?

Read the publication

Robert Popovian was published in Health Science Journal for a paper on prior authorization entitled An Estimate of the Net Benefits from Prior Authorization Policies in the U.S.

Read the publication

PODCASTS

Launch of GHLF News You Can Use podcast. A new podcast with a thought provoking take on health care news.

Listen here

Steven Newmark was featured on The Dermatology Digest podcast where he discussed the GHLF perspective on non-medical switching.

Listen here
**MAY**

*Comment letters*

5.5 – We joined a sign-on letter urging Blue Cross and Blue Shield of North Carolina and South Carolina to revise insurance coverage policy to ensure patients have a clear and less restrictive path to accessing infused gout therapy.

[Read the Letter About North Carolina Gout Medication Coverage Policies]

[Read the Letter About South Carolina Gout Medication Coverage Policies]

5.13 – We joined a sign-on letter in support of a bill that takes important steps in setting the protections Rhode Island patients need to maintain access to copay assistance programs.

[Read the Letter in Support of Rhode Island Bill S0859]

5.12 – We joined a sign-on letter to express concerns that H.R.3 will result in reduced access to provider-administered medications and the need to address rising costs for patients.

[Read the Letter to Speaker Pelosi about H.R.3]
OP-EDS

Morgan Fitzgerald, 50-State Network Patient Advocate, wrote an op-ed published in The Coast News. Morgan shares her story in support of reforming step therapy legislation to protect Californian’s access to medications.

Read the op-ed

Steven Newmark was featured in the May issue of Managed Healthcare Executive to talk about the impact of formulary exclusions.

Read the article

Stop Failing Patients | Read the article

PATIENT TESTIMONY

Migraine advocate, nurse and 50-State Network member Elizabeth Arant shares her story in hopes of helping others with migraine disease get access to better treatments regardless of their health care coverage plan.

Read the testimony

Director of Education and Digital Strategy at GHLF, Joseph Coe, provided testimony during a recent meeting of the New York State Drug Utilization Review Board. He hopes to help other New Yorkers with migraine disease get access to better treatments.

Read the testimony

Media Interviews

5.12 - Cash-based pharmacies deliver transparency, savings (Pharmacy Today)

Learn more
Comment Letters

6.21 – We wrote a comment letter to the Federal Trade Commission (FTC) to inform the Multilateral Pharmaceutical Merger Task Force’s review of how to approach and analyze the effects of pharmaceutical mergers.

Read the letter to the FTC

6.22 – We joined a sign-on letter in support of the continued use of human fetal tissue in research because it is an indispensable biomedical research tool crucial for life-saving biomedical research.

Read the letter in support of research using human fetal tissue

6.23 – We wrote a letter and signed on to two coalition letters responding to a request for information on pharmacy benefits and prescription drug costs. In our letter, we highlight three chief concerns: health insurers’ response to the use of copay assistance programs, a commitment to transparency, and the effect of drug rebates on access to care.

Read the letters:

GHLF comments on pharmacy benefits and prescription drug costs

Comment to federal departments on reporting on benefits and drug costs (ATAP Sign-on)

Comment to federal departments on reporting on benefits and drug costs (HIV+HEP Institute Sign-On)

6.30 – We joined a letter commenting on current drug pricing proposals and advocating for patient-centered policy solutions addressing copay assistance and pharmacy rebates.

Read the letter about patient centered drug pricing policies
Virtual Advocacy

Migraine proclamation passed the NY Senate.

Read the text of the resolution

We organized virtual meetings with Massachusetts state legislators about copay accumulator adjuster programs. The proposed legislation, Massachusetts Bill H.1053 / S.644, would make it that all coupons used would always count towards a patient’s deductible. We met with:

- Representative Marcos Devers
- Representative Daniel Carey
- Representative Steven Owens
- Representative Brian Ashe
- Representative David LeBoeuf
- Representative Daniel Carey
- Representative Mindy Domb
- Representative Claire Cronin
- Representative Patricia Duffy

During June, we invested positive energy to support our LGBTQ community. Throughout the month, our social media channels highlighted art created by member Sal Marx and featured other select members.
MEDIA

Louis Tharp and Zoe Rothblatt interview on the step therapy publication published on Helio.
Read the interview here

Article on our step therapy paper published, featuring interviews with Louis Tharp and Zoe Rothblatt, along with Dr. Schweitz, GHLF member Morgan and CreakyJoints member Yaideliz.
Read the article

Robert Popovian quoted in the capital journal that goes to every state legislator in the country.
Read the quotes here

Robert Popovian Op-Eds:
Morning Consult entitled “Innovation in Cancer Diagnostics Is the First Step in Ensuring Equity for All Patients.
Read the op-ed

Outsourced Pharma for a piece entitled “The US Drug Pricing System Needs to Be Fixed”.
Read the op-ed here

Pacific Research Institute national syndication: Waiving Covid-19 Vaccine Patents Is a Bad Idea and Sets a Dangerous Precedent
Read the op-ed here

AWARENESS

Raising the voice of migraine patients: During June’s Migraine Awareness Month, we participated in the Shades for Migraine social media campaign through posting fun pictures wearing sunglasses.
JULY

COMMENT LETTERS

7.1 – We signed on to a letter to the U.S. Senate Committee on Health, Education, Labor and Pensions urging the committee to prepare for future public health emergencies by passing legislation ensuring individuals can obtain an extra supply of medication.

Read the letter about medication in emergencies

7.28 - We joined a letter to the U.S. Department of Health and Human Services (HHS) encouraging the department to adopt policies to improve medication affordability through reducing the cost-sharing burden on patients.

Read the letter about improving patient drug affordability
Virtual Advocacy

We organized virtual meetings with Massachusetts state legislators about copay accumulator adjuster programs. The proposed legislation, Massachusetts Bill H.1053 / S.644, would make it that all coupons used would always count towards a patient’s deductible. We met with:

- Representative Patricia Duffy
- Representative Mindy Domb
- Representative Tricia Farley-Bouvier
- Senator Joseph A. Boncore

We have been virtually meeting with Pennsylvania legislators about bill S196. Like the Massachusetts bill, it would require that any cost-sharing amounts paid by the insured or on behalf of the insured would count towards the insured person’s cost sharing contribution requirements. We met with:

- Johnathan Humma
- Senator Lisa Boscola
- Senator Gene Yaw

Op-eds

Daniel Garza, Patient Advocate, wrote an Op-Ed published in the Stu News Laguna about the need for cancer diagnostic innovations. Read the letter here

Lou Tharp, Executive Director at GHLF, wrote an Op-Ed published in Health Science Journal about the bad idea for emergency room visits to not be covered (in the future) if the insurance company decides the visit was non-urgent. Read the Op-Ed here

Robert Popovian wrote an Op-Ed published in Bioprocess Online about why we should rescue the legislative intent of the BPCIA. Read the Op-Ed here

It is Time for Outcomes-Based Reimbursement for Biopharmaceuticals. Read the Op-Ed here

Why Should We Rescue The Legislative Intent Of The BPCIA?

By Peter J. Pitts, Robert Popovian, and Wayne Winegarden

What happens when regulatory ambiguity displaces sound scientific guidance, distorting the legislative intent of Congress? This is precisely the situation regarding the FDA changing the regulatory rules of the road regarding a biosimilar’s strength versus its potency. It is a distinction with a difference – with the potential unintended consequence of distorting pricing both the development and uptake of biosimilars. It is also important to consider the implications of the legislative intent of the Biologics Price Competition and Innovation Act of 2009 (BPCIA) and how it can be improved.
If you see local, state, or national policy that puts patients at risk, email us at advocacy@ghlf.org to further investigate. Our mission at the 50-State Network is to elevate the voices of the chronic illness community, so don’t hesitate to share your concerns.
COMMENT LETTERS

9.9 – We signed on to a letter to the House Committee on Education and Labor urging Congress to address the unaffordable out-of-pocket costs in the Medicare Part D program as the budget reconciliation package is drafted.

Read the letter about taking action to address out-of-pocket costs in Medicare Part D

9.10 – We signed on to a letter asking Congress to include step therapy protections for patients in the reconciliation package to ensure patients have timely access to the most medically appropriate treatment.

Read the letter in support of step therapy protections

VIRTUAL ADVOCACY

We met virtually with Pennsylvania Senator Amanda Cappelletti and her Legislative Director, Diane Stubblebine, about pending legislation that would require that any cost-sharing amounts paid by or on behalf of the insured would count towards the person’s cost sharing contribution requirements. Tien Sydnor Campbell, 50-State Network Patient Advocate, joined us and shared her experience with copay assistance programs.

We launched our tracker to show how much time patients have spent fighting to get their treatment. The project titled “Wish You Could Bill Your Insurance Company for All Those Wasted Hours? Raise Your Voice here” was created so we can show insurance companies and the public how much money every year chronic disease patients spend fighting for their care and how much patients should be compensated for that lost time. Learn more here

OP-EDS

Robert Popovian, Pharm. D., MS Chief Science Policy Officer at GHLF, wrote in an Op-Ed published in The Hill about the future of vaccines. Read more here

Elisa Comer, 50-State Network Advocate, contributed to an article about insurance denials of medication. Read more here

Robert Popovian wrote in Morning Consult: We Should Not Lose Sight of the Upcoming Flu Season. Read more here

BLOG

Robert Popovian published a blog post for the Progressive Policy Institute, Aiming Drug Price Reform at the Right Target. Read more here
**OCTOBER**

**COMMENT LETTERS**

**10.6** - We signed on to a letter to Congress focused on advancing policies and measures that improve prescription drug affordability and access for Americans.

*Read the letter about patient community concerns with drug pricing proposals*

**10.21** – We signed on to a letter urging Congress to avoid another continuing resolution by completing the Fiscal Year 2022 appropriations process before the current CR expires.

*Read the letter about FY22 appropriations process*

**10.18** – We wrote a letter and signed on to a letter to the New York Governor in support of a bill that will protect New Yorkers from non-medical switching by prohibiting a health plan from making prescription drug formulary changes during a plan year.

*Read the letter in support of New York S.4111/A.4668*

*Read the letter relating to non-medical switching*

10.18 – We wrote a letter to Michigan State Senator Curt VanderWall (R) who chairs the Health Policy and Human Services Committee in the Michigan Senate in support of HB 4353 that would require all payment made by patients, directly or on their behalf, to be counted toward their overall out-of-pocket maximum amount or deductible.

*Read the letter in support of Michigan HB.4353*

10.6 - We signed on to a letter to the Ohio House Commerce and Labor Committee opposing HB 435 which would give Ohio employees a series of exemptions when it comes to getting the COVID-19 vaccine.

*Read the letter opposing HB 435*

**Media Interviews**

10.01 – Robert Popovian: Walmart–Novo Nordisk insulin offers deep discounts to select few (Pharmacy Today)

*Learn more*
Podcasts

We launched GHLF Healthcare Matters podcast. A new podcast that pulls back the curtain to help you make sense of complex healthcare economics and policy issues.

Listen Here

Formerly GHLF News You Can Use, re-launched as The Health Advocates for season two. A podcast that breaks down major health news of the week to help you make sense of it all.

Listen Here

OP-EDS

Benefit Design In Medicare Exacerbates Vaccine Access Inequity.

Read more here
November

Comment Letters

11.2 – We wrote a letter asking the FDA for more clarity on safety warnings for Janus kinase inhibitor medications so we can communicate this important information to the millions of patients living with chronic diseases.

Read the letter to FDA Acting Commissioner Woodcock Regarding JAK Inhibitor Warnings

11.23 – We wrote a letter to the Center for Consumer Information and Insurance Oversight (CCIIO) to express our concern with current policies regarding copay accumulator adjustors and our support for reform language to be added into the upcoming Notice of Benefit and Payment Parameters 2023.

Read the letter to CCIIO Regarding Accumulator Adjustor Policies

December

Comment Letters

11.13 – We signed on to a letter in support of provisions to improve vaccine coverage through providing access to adult vaccines under Medicaid and CHIP and removing cost-sharing for recommended vaccines.

Read the letter to Senator Schumer about the vaccines provisions in the Build Back Better Act

12.14 – We signed on to a letter urging for the protection of the Orphan Drug Tax Credit in the Build Back Better legislation.

Read the letter to senate leadership and the Senate Committees on Budget and Finance

12.20 – We wrote a letter to Senator Schumer asking questions regarding the potential implementation of the Build Back Better Act. We asked about who will set prices, the impact on generics and biosimilars, and drug rebates and formulary construction.

Read the letter to Senator Schumer about the Build Back Better Act
**IBD Awareness**

In the first week of December, GHLF participated in Crohn’s and Colitis Awareness Week through social media by sharing our top resources for living with inflammatory bowel disease.

**Media Interviews**

**12.31** – Covid-19 vaccines and antiviral treatments

[Learn more](#)

**KEY LEGISLATION PASSED**

**Copay Accumulator Adjustors**

- Arkansas HB 1569
- Connecticut SB 1003
- Louisiana SB 94
- Kentucky SB 45
- North Carolina SB 257
- Oklahoma HB 2678
- Tennessee HB 619

**Step Therapy**

- Arizona SB 1270
- Arkansas SB 99
- California AB 347
- Louisiana HB 263
- Nebraska LB 337